Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser RA, Lyons KE, McClain T, et al. (2009). Movement Disorders.
Summary
A small placebo-controlled pilot of intravenous glutathione in 21 people with Parkinson's disease whose motor symptoms were not adequately controlled by their existing medication, given three times a week for four weeks. It was well tolerated, with no withdrawals for adverse events and similar adverse events in both groups, but there were no significant differences in Unified Parkinson's Disease Rating Scale scores between glutathione and placebo. A negative pilot, and the main published trial of glutathione given by infusion.